S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
T   39.50 (+1.41%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
BAC   32.93 (+0.70%)
DIS   144.67 (-1.69%)
Log in

Paladin Labs Stock Price, Forecast & Analysis (TSE:PLB)

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Paladin Labs Inc is a specialty pharmaceutical company focused on developing, acquiring, in-licensing, marketing and distributing pharmaceutical products. The Company's product portfolio includes Tridural, Abstral and Trelstar. Tridural is a once-a-day tramadol product indicated as a first-line therapy for adults with moderate pain requiring several days or more of treatment. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
CIKN/A
Phone+1-514-3401112

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive PLB News and Ratings via Email

Sign-up to receive the latest news and ratings for PLB and its competitors with MarketBeat's FREE daily newsletter.


Paladin Labs (TSE:PLB) Frequently Asked Questions

What is Paladin Labs' stock symbol?

Paladin Labs trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PLB."

Has Paladin Labs been receiving favorable news coverage?

News coverage about PLB stock has trended somewhat negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Paladin Labs earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Paladin Labs.

What other stocks do shareholders of Paladin Labs own?

How do I buy shares of Paladin Labs?

Shares of PLB and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Paladin Labs' official website?

The official website for Paladin Labs is http://www.paladinlabs.com/.

How can I contact Paladin Labs?

Paladin Labs' mailing address is 100 Alexis-Nihon Blvd Suite 600, SAINT-LAURENT, QC H4M 2P2, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-3401112.


MarketBeat Community Rating for Paladin Labs (TSE PLB)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  200
MarketBeat's community ratings are surveys of what our community members think about Paladin Labs and other stocks. Vote "Outperform" if you believe PLB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Featured Article: Growth Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel